AdAlta Ltd (ASX:1AD) CEO Tim Oldham tells Proactive the company has successfully dosed the first participants in its AD-214 Phase I extension study, marking the next milestone in the drug's development. AD-214 is being developed to target fibrotic diseases. AdAlta is on track to achieve interim results from the study before the end of 2023, providing a glimpse into the drug's potential. The final assessment visits are expected to be completed, and full results are anticipated to be available in the first quarter of 2024. AdAlta will hold an online briefing discussing progress of the AD-214 Phase 1 extension study on Thursday, August 10, at 10:30am (AEDT). To participate in the live webcast, shareholders, investors and interested parties are invited to click on the link to register: https://us02web.zoom.us/webinar/register/WN_eLqmq8iTSYSxx_mXUV0dlg
AdAlta back in the clinic with AD-214
